Skip to main content
Premium Trial:

Request an Annual Quote

Bruker Projects Q2 Revenues of $420M-$425M, Exceeding Analyst Expectations

NEW YORK - Bruker said today in a filing with the US Securities and Exchange Commission that it expects Q2 2020 revenues of around $420 million to $425 million.

That figure would represent a decline of 13 percent to 14 percent from $490 million in Q2 2019 but would beat analysts' average estimate of $388.8 million.

Bruker had previously projected a year-over-year revenue decline of between 15 percent and 25 percent for the quarter.

The Billerica, Massachusetts-based company said that the better-than-expected projections were driven mainly by stronger demand for its life science products.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more